A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

Study Objective

The objective of this prospective, observational registry is to document the characteristics and
management of patients with mCRPC in routine clinical practice, independent of treatment used.

This will be based on documentation and description of the following:
• sequencing of treatment initiation, termination, and duration;
• relative effectiveness of treatments;
• defined medical resource utilization and quality-of-life parameters;
• follow-up for survival.

Participation conditions

Patients eligible for enrolment will be men aged at least 18 years, with a confirmed diagnosis of adenocarcinoma of the prostate, documented metastatic prostate cancer, and progression despite surgical or medical castration (defined as testosterone levels <50 ng/dL [<1.7 nmol/L]). Patients will be enrolled at the time of initiating a new systemic mCRPC treatment or during surveillance.

Centre Hospitalier de Luxembourg (CHL)